Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Author index

Page Path
HOME > Browse articles > Author index
Search
Jiyeon Hyeon 2 Articles
Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas
Seok-Jin Kim, Jiyeon Hyeon, Inju Cho, Young Hyeh Ko, Won Seog Kim
Cancer Res Treat. 2019;51(2):611-622.   Published online July 20, 2018
DOI: https://doi.org/10.4143/crt.2018.191
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Pembrolizumab, a programmed cell death protein 1 (PD1) inhibitor inhibits the interplay between PD1 of T-cell and programmed cell death ligand 1 (PDL1) on tumor cells. Although pembrolizumab has been tried to various subtypes of non-Hodgkin lymphoma (NHL), realworld data about the efficacy of pembrolizumab in NHL patients are limited.
Materials and methods
We analyzed the outcome of 30 relapsed or refractory NHL patients treated with pembrolizumab, and compared the outcome between Epstein-Barr virus (EBV)‒positive and negative subtypes because EBV infection of tumor cells can upregulate PDL1 expression.
Results
Seven patients with EBV-positive NHL showed a response including NK/T-cell lymphoma (6/14, 44%) and primary mediastinal B-cell lymphoma (1/4, 25%) whereas EBV-negative subtypes did not respond such as diffuse large B-cell lymphoma and T-lymphoblastic lymphoma. We also evaluated PDL1 expression using tumor tissue of 76 patients. High PDL1 expression (positive staining of > 50% of tumor cells) was more frequent in NK/T-cell lymphoma and primary mediastinal B-cell lymphoma than other subtypes. Thus, PDL1 expression was significantly higher in EBV-positive (18/32, 56%) than EBV-negative NHL (4/38, 11%, p < 0.001). Furthermore, NK/T-cell lymphoma patients with high PDL1 expression showed a higher response (4/6, 67%) than those with low PDL1 expression (1/5, 20%).
Conclusion
Pembrolizumab could be useful as a salvage treatment for relapsed or refractory EBV-positive NHL, especially NK/T-cell lymphoma. However, its efficacy in EBV-negative NHL with low or absent PDL1 expression is still not clear although pembrolizumab could be a potential treatment option for relapsed or refractory NHL.

Citations

Citations to this article as recorded by  
  • Tislelizumab and Radiation Therapy in Low-Risk Early-Stage Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: A Phase II Study Protocol
    Jia-Ying Li, Shu-Nan Qi, Chen Hu, Xin Liu, Yong Yang, Tao Wu, Rong Zheng, Xiao-Li Feng, Xiao-Guang Ni, Feng-Yan Jin, Yu-Qin Song, Wei-Ping Liu, Sheng-Yu Zhou, Ye-Xiong Li
    Future Oncology.2024; 20(5): 245.     CrossRef
  • Therapeutic Monoclonal Antibodies for Non-Hodgkin Lymphoma: A Literature Review
    Mohammad Sadegh Fallahi, Nasibeh Zerangian, Atousa Ghorbani, Gisou Erabi, Melika Shirali, Elaheh Shabani, Foad Rommasi, Mahsa Mohammadi Najafabadi, Shima Karbasi, Samaneh Toutounchian, Ramin Ahangar-Sirous, Ava Motaghy, Mahsa Heidari, Niloofar Deravi
    Current Cancer Therapy Reviews.2024; 20(1): 53.     CrossRef
  • The IPTA Nashville consensus conference on post‐transplant lymphoproliferative disorders after solid organ transplantation in children: IV‐consensus guidelines for the management of post‐transplant lymphoproliferative disorders in children and adolescents
    Upton D. Allen, Arnaud G. L'Huillier, Catherine M. Bollard, Thomas G. Gross, Robert J. Hayashi, Britta Höcker, Britta Maecker‐Kolhoff, Stephen D. Marks, George Vincent Mazariegos, Francoise Smets, Ralf U. Trappe, Gary Visner, Richard E. Chinnock, Patrizia
    Pediatric Transplantation.2024;[Epub]     CrossRef
  • Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea
    Ji Yun Lee, Ji Hyun Kwon, Joon Young Hur, Jun Ho Yi, Ji Hyun Lee, Hyungwoo Cho, Young Rok Do, Jae-Cheol Jo, Hye Jin Kang, Yougil Koh, Won Sik Lee, Sung Nam Lim, Sang Eun Yoon, Seok Jin Kim, Jeong-Ok Lee
    Cancer Research and Treatment.2024; 56(2): 681.     CrossRef
  • Counterproductive effects of anti-CD38 and checkpoint inhibitor for the treatment of NK/T cell lymphoma
    Wendy W. L. Lee, Jing Quan Lim, Tiffany P. L. Tang, Daryl Tan, Ser Mei Koh, Kia Joo Puan, Liang Wei Wang, Jackwee Lim, Kim Peng Tan, Wee Joo Chng, Soon Thye Lim, Choon Kiat Ong, Olaf Rotzschke
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art
    Magda Zanelli, Valentina Fragliasso, Paola Parente, Alessandra Bisagni, Francesca Sanguedolce, Maurizio Zizzo, Giuseppe Broggi, Stefano Ricci, Andrea Palicelli, Moira Foroni, Fabrizio Gozzi, Pietro Gentile, Andrea Morini, Nektarios Koufopoulos, Rosario Ca
    International Journal of Molecular Sciences.2024; 25(12): 6447.     CrossRef
  • EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk‐stratification, and management
    Luis Malpica, Mario L. Marques‐Piubelli, Brady E. Beltran, Julio C. Chavez, Roberto N. Miranda, Jorge J. Castillo
    American Journal of Hematology.2024; 99(10): 2002.     CrossRef
  • Multiplexed Spatial Profiling of Hodgkin Reed–Sternberg Cell Neighborhoods in Classic Hodgkin Lymphoma
    Maryam Pourmaleki, Caitlin J. Jones, Sabrina D. Mellinghoff, Brian D. Greenstein, Priyadarshini Kumar, Miguel Foronda, Daniel A. Navarrete, Carl Campos, Mikhail Roshal, Nikolaus Schultz, Sohrab P. Shah, Andrea Schietinger, Nicholas D. Socci, Travis J. Hol
    Clinical Cancer Research.2024; 30(17): 3881.     CrossRef
  • PD-1 inhibitors plus chemotherapy for refractory EBV-positive DLBCL: a retrospective analysis
    Youli Li, Yonghe Wu, Sufen Cao, Baohua Yu, Qunling Zhang, Zuguang Xia, Junning Cao, Fangfang Lv, Guang-Liang Chen
    Blood Research.2024;[Epub]     CrossRef
  • A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma
    Mwanasha H. Merrill, Parastoo B. Dahi, Robert A. Redd, Mikaela M. McDonough, Yi-Bin Chen, Zachariah DeFilipp, Alex F. Herrera, David C. Fisher, Ann S. LaCasce, Oreofe O. Odejide, Samuel Y. Ng, Caron A. Jacobson, Reid W. Merryman, Austin I. Kim, Yago L. Ni
    Blood.2023; 142(7): 621.     CrossRef
  • The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis
    Yanxia He, Yan Gao, Liqin Ping, Haixia He, Cheng Huang, Bing Bai, Xiaoxiao Wang, Zhiming Li, Qingqing Cai, Yuhua Huang, Xueyi Pan, Wenbin Zeng, Yanan Liu, Huiqiang Huang
    Journal of Cancer Research and Clinical Oncology.2023; 149(5): 2017.     CrossRef
  • Resistance mechanisms of immune checkpoint inhibition in lymphoma: Focusing on the tumor microenvironment
    Chunlan Zhang, Leiming Wang, Caigang Xu, Heng Xu, Yu Wu
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • The Role of NK Cells in EBV Infection and Related Diseases: Current Understanding and Hints for Novel Therapies
    Maria G. Desimio, Daniela A. Covino, Beatrice Rivalta, Caterina Cancrini, Margherita Doria
    Cancers.2023; 15(6): 1914.     CrossRef
  • Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer
    Jie Zhou, Guanming Chen, Jiuling Wang, Bo Zhou, Xuemin Sun, Jinsong Wang, Shu Tang, Xiangju Xing, Xiaofei Hu, Yang Zhao, Yu Peng, Wenjiong Shi, Tingting Zhao, Yuzhang Wu, Hanbing Zhong, Ni Hong, Zhihua Ruan, Yi Zhang, Wenfei Jin
    Oncogenesis.2023;[Epub]     CrossRef
  • Education and Empowering Special Forces to Eradicate Secret Defectors: Immune System-Based Treatment Approaches for Mature T- and NK-Cell Malignancies
    Till Braun, Alexandra Schrader
    Cancers.2023; 15(9): 2532.     CrossRef
  • Efficacy of Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Narrative Review
    Sarah Perdikis-Prati, Semira Sheikh, Antonin Bouroumeau, Noémie Lang
    Biomedicines.2023; 11(6): 1720.     CrossRef
  • First‐line immunotherapy with anti‐PD‐1 antibody for extranodal NK/T‐cell lymphoma: A retrospective study
    Xiaoxiao Wang, Lei Wen, Jing Liao, Yanfen Feng, Yuhong Li, Zhaoming Zhou, Cheng Zhou, Huiqiang Huang
    British Journal of Haematology.2023; 202(4): 812.     CrossRef
  • Advances and challenges of immunotherapies in NK/T cell lymphomas
    Ling He, Na Chen, Lei Dai, Xingchen Peng
    iScience.2023; 26(11): 108192.     CrossRef
  • Adult's Epstein–Barr virus‐associated hemophagocytic lymphohistiocytosis: A case report
    Yi Sun, Han Yao, Xiaofeng Yu, Yunzhao Chen, Chen Chai
    Clinical Case Reports.2023;[Epub]     CrossRef
  • Serious consequences of Epstein‐Barr virus infection: Hemophagocytic lymphohistocytosis
    Lingyue Xu, Xiaofang Guo, Hongzai Guan
    International Journal of Laboratory Hematology.2022; 44(1): 74.     CrossRef
  • Update on Molecular Diagnosis in Extranodal NK/T-Cell Lymphoma and Its Role in the Era of Personalized Medicine
    Ka-Hei (Murphy) Sun, Yin-Ting (Heylie) Wong, Ka-Man (Carmen) Cheung, Carmen (Michelle) Yuen, Yun-Tat (Ted) Chan, Wing-Yan (Jennifer) Lai, Chun (David) Chao, Wing-Sum (Katie) Fan, Yuen-Kiu (Karen) Chow, Man-Fai Law, Ho-Chi (Tommy) Tam
    Diagnostics.2022; 12(2): 409.     CrossRef
  • The Epstein-Barr Virus Hacks Immune Checkpoints: Evidence and Consequences for Lymphoproliferative Disorders and Cancers
    Alison Felipe Bordini Biggi, Deilson Elgui de Oliveira
    Biomolecules.2022; 12(3): 397.     CrossRef
  • Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
    Xi Chen, Wanchun Wu, Wenwen Wei, Liqun Zou
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk‐stratification, and management
    Luis Malpica, Mario L. Marques‐Piubelli, Brady E. Beltran, Julio C. Chavez, Roberto N. Miranda, Jorge J. Castillo
    American Journal of Hematology.2022; 97(7): 951.     CrossRef
  • Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions
    John C. Reneau, Polina Shindiapina, Zachary Braunstein, Youssef Youssef, Miguel Ruiz, Saira Farid, Walter Hanel, Jonathan E. Brammer
    Journal of Clinical Medicine.2022; 11(10): 2699.     CrossRef
  • Cellular Origins and Pathogenesis of Gastrointestinal NK- and T-Cell Lymphoproliferative Disorders
    Susan Swee-Shan Hue, Siok-Bian Ng, Shi Wang, Soo-Yong Tan
    Cancers.2022; 14(10): 2483.     CrossRef
  • Epi‐immunotherapy for cancers: rationales of epi‐drugs in combination with immunotherapy and advances in clinical trials
    Yang Xu, Ping Li, Yang Liu, Dijia Xin, Wen Lei, Aibin Liang, Weidong Han, Wenbin Qian
    Cancer Communications.2022; 42(6): 493.     CrossRef
  • Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
    N Nora Bennani, Hyo Jin Kim, Levi D Pederson, Pamela J Atherton, Ivana N Micallef, Gita Thanarajasingam, Grzegorz S Nowakowski, Thomas Witzig, Andrew L Feldman, Stephen M Ansell
    Journal for ImmunoTherapy of Cancer.2022; 10(6): e004984.     CrossRef
  • Approaches to spatially resolving the tumour immune microenvironment of hepatocellular carcinoma
    Felix Marsh-Wakefield, Angela L Ferguson, Ken Liu, Cositha Santhakumar, Geoffrey McCaughan, Umaimainthan Palendira
    Therapeutic Advances in Medical Oncology.2022;[Epub]     CrossRef
  • Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management
    Eric Tse, Christopher P. Fox, Alexander Glover, Sang Eun Yoon, Won Seog Kim, Yok-Lam Kwong
    Seminars in Hematology.2022; 59(4): 198.     CrossRef
  • Exosomal and Soluble Programed Death-Ligand 1 (PD-L1) Predicts Responses to Pembrolizumab in Patients with Extranodal NK/T-Cell Lymphoma
    Seok Jin Kim, Kyung Ju Ryu, Bon Park, Sang Eun Yoon, Junhun Cho, Yoon Park, Won Seog Kim
    Cancers.2022; 14(22): 5618.     CrossRef
  • Characterization of Artificial Pneumothorax-Unrelated Pyothorax-Associated Lymphoma
    Guang-Liang Chen, Zu-Guang Xia, Jia Jin, Bao-Hua Yu, Junning Cao, Amir Radfar
    Journal of Oncology.2021; 2021: 1.     CrossRef
  • Graft Versus Host Disease Associated with Immune Checkpoint Inhibitors: A Pharmacovigilance Study and Systematic Literature Review
    Lee S. Nguyen, Lisa Raia, Bénédicte Lebrun-Vignes, Joe-Elie Salem
    Frontiers in Pharmacology.2021;[Epub]     CrossRef
  • Pulmonary Lymphoepithelioma-Like Carcinoma Treated with Immunotherapy or Chemotherapy: A Single Institute Experience
    Yang Fu, Yue Zheng, Pei-Pei Wang, Yue-Yun Chen, Zhen-Yu Ding
    OncoTargets and Therapy.2021; Volume 14: 1073.     CrossRef
  • EBV et immunodépression
    Y. Dieudonne, M. Martin, A.-S. Korganow, D. Boutboul, A. Guffroy
    La Revue de Médecine Interne.2021; 42(12): 832.     CrossRef
  • PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma
    Joshua W. D. Tobin, Karolina Bednarska, Ashlea Campbell, Colm Keane
    Cells.2021; 10(5): 1152.     CrossRef
  • NK-/T-cell lymphomas
    Hua Wang, Bi-bo Fu, Robert Peter Gale, Yang Liang
    Leukemia.2021; 35(9): 2460.     CrossRef
  • The role of EBV in haematolymphoid proliferations: emerging concepts relevant to diagnosis and treatment
    Emad Ababneh, Anas M Saad, Genevieve M Crane
    Histopathology.2021; 79(4): 451.     CrossRef
  • Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study
    Won Seog Kim, Yasuhiro Oki, Seok Jin Kim, Sang Eun Yoon, Kirit M. Ardeshna, Yi Lin, Jia Ruan, Pierluigi Porcu, Jonathan E. Brammer, Eric D. Jacobsen, Dok Hyun Yoon, Cheolwon Suh, Felipe Suarez, John Radford, Lihua E. Budde, Jin Seok Kim, Emmanuel Bachy, H
    Annals of Hematology.2021; 100(10): 2529.     CrossRef
  • The Role of Epstein–Barr virus-encoded Latent Membrane Proteins in Host Immune Escape
    Yuanyuan Jiang, Yuan Ding, Shuzhen Liu, Bing Luo
    Future Virology.2021; 16(8): 565.     CrossRef
  • EBV-Driven Lymphoproliferative Disorders and Lymphomas of the Gastrointestinal Tract: A Spectrum of Entities with a Common Denominator (Part 1)
    Magda Zanelli, Francesca Sanguedolce, Andrea Palicelli, Maurizio Zizzo, Giovanni Martino, Cecilia Caprera, Valentina Fragliasso, Alessandra Soriano, Luca Valle, Stefano Ricci, Alberto Cavazza, Francesco Merli, Stefano A. Pileri, Stefano Ascani
    Cancers.2021; 13(18): 4578.     CrossRef
  • Chemorefractory extranodal nasal-type natural-killer/T-cell lymphoma with great response to pembrolizumab in a young patient: a case report
    Fatemeh Adabifirouzjaei, Bharam Khazai, Ghazaleh Azami, Ghazaleh Shoja-e-Razavi
    Journal of Medical Case Reports.2021;[Epub]     CrossRef
  • Clinical and Therapeutic Implications of Epstein–Barr Virus in HIV-Related Lymphomas
    Miriam Verdu-Bou, Gustavo Tapia, Agueda Hernandez-Rodriguez, Jose-Tomas Navarro
    Cancers.2021; 13(21): 5534.     CrossRef
  • Regulation of the Immune Checkpoint Indoleamine 2,3-Dioxygenase Expression by Epstein–Barr Virus
    Leila Sawada, Antonio Carlos Rosário Vallinoto, Igor Brasil-Costa
    Biomolecules.2021; 11(12): 1792.     CrossRef
  • Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors
    Alejandro Olivares-Hernández, Luis Figuero-Pérez, José Pablo Miramontes-González, Álvaro López-Gutiérrez, Rogelio González-Sarmiento, Juan Jesús Cruz-Hernández, Emilio Fonseca-Sánchez
    Life.2021; 11(12): 1400.     CrossRef
  • EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2020 update on diagnosis, risk‐stratification and management
    Brady E. Beltran, Denisse Castro, Sally Paredes, Roberto N. Miranda, Jorge J. Castillo
    American Journal of Hematology.2020; 95(4): 435.     CrossRef
  • Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression
    Junhun Cho, Seok Jin Kim, Woong-Yang Park, Jinho Kim, Jeongmin Woo, Gahyun Kim, Sang Eun Yoon, Young Hyeh Ko, Won Seog Kim
    Modern Pathology.2020; 33(4): 603.     CrossRef
  • PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation
    Matthew J. Frigault, Philippe Armand, Robert A. Redd, Erin Jeter, Reid W. Merryman, Kimberly C. Coleman, Alex F. Herrera, Parastoo Dahi, Yago Nieto, Ann S. LaCasce, David C. Fisher, Samuel Y. Ng, Oreife O. Odejide, Arnold S. Freedman, Austin I. Kim, Jenni
    Blood Advances.2020; 4(1): 122.     CrossRef
  • Checkmate for EBV-HLH
    Nader Kim El-Mallawany, Kenneth L. McClain
    Blood.2020; 135(11): 782.     CrossRef
  • CDC27 Promotes Tumor Progression and Affects PD-L1 Expression in T-Cell Lymphoblastic Lymphoma
    Yue Song, Wei Song, Zhaoming Li, Wenting Song, Yibo Wen, Jiwei Li, Qingxin Xia, Mingzhi Zhang
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Stage IV natural killer/T-cell lymphoma with chronic active Epstein–Barr virus, treated with pembrolizumab and TCRαβ-depleted haploidentical hematopoietic stem cell transplantation
    Yeong Eun Kim, Hyery Kim, Juhee Shin, So Yoon Min, Sung Han Kang, Jin Kyung Suh, Kyung-Nam Koh, Ho Joon Im
    Leukemia & Lymphoma.2020; 61(9): 2250.     CrossRef
  • Virus-Specific T Cells for the Treatment of Malignancies—Then, Now, and the Future
    Sandhya Sharma, Wingchi K Leung, Helen E Heslop
    Current Stem Cell Reports.2020; 6(2): 17.     CrossRef
  • The roles of programmed death ligand 1 in virus-associated cancers
    Morvarid Golrokh Mofrad, Donya Taghizadeh Maleki, Ebrahim Faghihloo
    Infection, Genetics and Evolution.2020; 84: 104368.     CrossRef
  • Immune-Checkpoint Blockade Therapy in Lymphoma
    Ayumi Kuzume, SungGi Chi, Nobuhiko Yamauchi, Yosuke Minami
    International Journal of Molecular Sciences.2020; 21(15): 5456.     CrossRef
  • Multiplex immunohistochemistry in lymphoma pathology: a research tool for study of the immune microenvironment
    Matthew Pugh, Ayse U. Akarka, Kelly Hunter, Stefan Dojcinov, Teresa Marafioti
    Diagnostic Histopathology.2020; 26(9): 407.     CrossRef
  • Targeting immune checkpoints in hematological malignancies
    Basit Salik, Mark J. Smyth, Kyohei Nakamura
    Journal of Hematology & Oncology.2020;[Epub]     CrossRef
  • Targeted Therapies for Epstein-Barr Virus-Associated Lymphomas
    Yonggang Pei, Josiah H. Y. Wong, Erle S. Robertson
    Cancers.2020; 12(9): 2565.     CrossRef
  • Immunology of EBV-Related Lymphoproliferative Disease in HIV-Positive Individuals
    Polina Shindiapina, Elshafa H. Ahmed, Anna Mozhenkova, Tamrat Abebe, Robert A. Baiocchi
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches
    Ji-Yoon Noh, Huiyun Seo, Jungwoon Lee, Haiyoung Jung
    International Journal of Molecular Sciences.2020; 21(21): 8000.     CrossRef
  • EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas
    Danielle L.V. Maracaja, Vidya Puthenpura, Salley G. Pels, Dennis P. O’Malley, Jeffrey L. Sklar, Karin E. Finberg, Mina L. Xu
    Applied Immunohistochemistry & Molecular Morphology.2020; 28(10): 725.     CrossRef
  • Current Immunotherapy Approaches in Non-Hodgkin Lymphomas
    Robert Pytlik, Kamila Polgarova, Jana Karolova, Pavel Klener
    Vaccines.2020; 8(4): 708.     CrossRef
  • Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review
    Zheng Yan, Shuna Yao, Yanyan Liu, Jianbo Zhang, Peng Li, Haiying Wang, Junfeng Chu, Shuang Zhao, Zhihua Yao
    Frontiers in Oncology.2020;[Epub]     CrossRef
  • Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study
    Seok Jin Kim, Jing Quan Lim, Yurike Laurensia, Junhun Cho, Sang Eun Yoon, Ji Young Lee, Kyung Ju Ryu, Young Hyeh Ko, Youngil Koh, Duck Cho, Soon Thye Lim, Marie Beck Enemark, Francesco D’Amore, Mette Bjerre, Choon Kiat Ong, Won Seog Kim
    Blood.2020; 136(24): 2754.     CrossRef
  • Pembrolizumab

    Reactions Weekly.2019; 1754(1): 273.     CrossRef
  • Immune checkpoint inhibitors in the treatment of virus-associated cancers
    Peipei Gao, Cordelle Lazare, Canhui Cao, Yifan Meng, Ping Wu, Wenhua Zhi, Shitong Lin, Juncheng Wei, Xiaoyuan Huang, Ling Xi, Gang Chen, Junbo Hu, Ding Ma, Peng Wu
    Journal of Hematology & Oncology.2019;[Epub]     CrossRef
  • 13,341 View
  • 618 Download
  • 71 Web of Science
  • 65 Crossref
Close layer
Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases in Korea: A Clinicopathological Analysis of 72 Cases in a Single Institute
Yooju Shin, Sang Yun Ha, Jiyeon Hyeon, Boram Lee, Jeeyun Lee, Kee-Taek Jang, Kyoung-Mee Kim, Young Suk Park, Cheol-Keun Park
Cancer Res Treat. 2015;47(4):738-746.   Published online February 16, 2015
DOI: https://doi.org/10.4143/crt.2014.224
AbstractAbstract PDFPubReaderePub
Purpose
Management of gastroenteropancreatic (GEP) neuroendocrine tumors with liver metastases (NETLM) presents many clinical challenges. Assessment of the extent of disease and primary tumor site is crucial for management. In this study, we investigated the primary tumor sites and prognostic factors in GEP NETLM among Korean patients. Materials and Methods We reviewed the medical records of 72 Korean patients diagnosed with GEP NETLM between January 1999 and May 2013, focusing on their clinical and pathologic characteristics.
Results
The most frequently encountered primary tumor sites were the pancreas (n=25, 35%), stomach (n=8, 11%), gall bladder (n=4, 6%) and rectum (n=3, 4%). Twenty-five patients (35%) had occult primary tumor. Twelve patients (17%) had histological grade G1 tumors, 30 patients (42%) had G2 tumors, and 30 patients (42%) had G3 tumors. The mean follow-up period after histological confirmation of hepatic metastases was 11.30±2.44 months for G3 tumors, 19.67±4.09 months for G2 tumors, and 30.67±6.51 months for G1 tumors. Multivariate analyses revealed that an unknown primary tumor site (p=0.001) and higher histological grade (p < 0.001) were independent prognostic indicators for shorter overall survival (OS). Most long-term survivors (OS > 24 months) had received antitumor treatment. Conclusion The primary tumor site most frequently associated with GEP NETLM was the pancreas. Unknown primary tumor and higher histological grade were independent prognostic indicators for shorter OS. Patients identified as being at a risk of shorter OS should be followed up closely.

Citations

Citations to this article as recorded by  
  • Clinicopathological Characteristics of Nonfunctional Pancreatic Neuroendocrine Neoplasms and the Effect of Surgical Treatment on the Prognosis of Patients with Liver Metastases: A Study Based on the SEER Database
    Abuduhaibaier Sadula, Gang Li, Dianrong Xiu, Chen Ye, Siqian Ren, Xin Guo, Chunhui Yuan, Min Tang
    Computational and Mathematical Methods in Medicine.2022; 2022: 1.     CrossRef
  • Effects of tumor origins and therapeutic options on the prognosis of hepatic neuroendocrine tumors
    Xiaoxiao Jiao, Wenqing Luan, Xiaoqian Peng, Lu Liu, Lianfeng Zhang, Lin Zhou
    Medicine.2020; 99(51): e23655.     CrossRef
  • Analysis of B-ultrasound and contrast-enhanced ultrasound characteristics of different hepatic neuroendocrine neoplasm
    Xiao-Ning Kang, Xiao-Yu Zhang, Jie Bai, Zun-Yi Wang, Wen-Jie Yin, Li Li
    World Journal of Gastrointestinal Oncology.2019; 11(5): 436.     CrossRef
  • Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies
    Lingaku Lee, Tetsuhide Ito, Robert T Jensen
    Expert Review of Anticancer Therapy.2019; 19(12): 1029.     CrossRef
  • A Case Report: Gastric Mixed Neuroendocrine-Nonneuroendocrine Neoplasm with Aggressive Neuroendocrine Component
    Quang Duy Pham, Ichiro Mori, Robert Y. Osamura
    Case Reports in Pathology.2017; 2017: 1.     CrossRef
  • Pancreatic neuroendocrine tumor Grade 1 patients followed up without surgery: Case series
    Mitsuru Sugimoto, Tadayuki Takagi, Rei Suzuki, Naoki Konno, Hiroyuki Asama, Ko Watanabe, Jun Nakamura, Hitomi Kikuchi, Yuichi Waragai, Mika Takasumi, Satoshi Kawana, Yuko Hashimoto, Takuto Hikichi, Hiromasa Ohira
    World Journal of Clinical Oncology.2017; 8(3): 293.     CrossRef
  • Gastroenteropancreatic—origin neuroendocrine carcinomas
    Yong Gyun Won, Kyung-Jin Seo, Jiyeon Hyeon, Ok Ran Shin, Eundeok Chang, Der Sheng Sun, Hae Sung Won, Yoon Ho Ko, Sae Jung Na, Su Lim Lee, Young Mi Ku, Dong Soo Lee
    Medicine.2017; 96(49): e9009.     CrossRef
  • A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases
    Liangtao Ye, Huilin Ye, Quanbo Zhou, Zhihua Li, Qing Lin, Langping Tan, Wenchao Gao, Zhiqiang Fu, Shangyou Zheng, Rufu Chen
    International Journal of Surgery.2016; 29: 108.     CrossRef
  • Liver Metastasis of Gastrointestinal Neuroendocrine Tumors: A Single Center Experience
    Bita Geramizadeh, Ali Kashkooe, Seyed Ali Malekhosseini
    Hepatitis Monthly.2016;[Epub]     CrossRef
  • Neuroendocrine neoplasms of liver - A 5-year retrospective clinico-pathological study applying World Health Organization 2010 classification
    Deepak Kalyansingh Burad, Thomas Alex Kodiatte, Sayd Mohamed Rajeeb, Ashish Goel, Chundamannil Eapen Eapen, Banumathi Ramakrishna
    World Journal of Gastroenterology.2016; 22(40): 8956.     CrossRef
  • Unusual endoscopic findings of gastric neuroendocrine tumor
    Kazuhiro Kishi, Akihiko Fujisawa, Minoru Horikita, Yoshihiro Nakai, Kazushi Ooshimo, Fumiko Kishi, Masako Kimura, Chun-che Lin, Tetsuji Takayama
    The Journal of Medical Investigation.2015; 62(3.4): 251.     CrossRef
  • 11,914 View
  • 77 Download
  • 11 Web of Science
  • 11 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP